Results 151 to 160 of about 333,176 (311)
In this study, a MXene‐based V4C3 nanoplatform, VARH, was constructed, which achieved a photothermal conversion efficiency of 44.21% in the NIR‐II window. This platform integrated photothermal therapy, chemodynamic therapy, and thermodynamic therapy with CRISPR/Cas9‐mediated heat shock protein 90 knock‐out technology.
Zi‐Jian Huang +8 more
wiley +1 more source
Malignancy of Urinary Tract in Kidney Transplant Recipients-A Narrative Review. [PDF]
Małyszko SJ +8 more
europepmc +1 more source
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
Microbiota management: a perspective for kidney transplant patients. [PDF]
Souza CS, Camara NOS, Alves-Silva T.
europepmc +1 more source
A dual‐network bFGF@CB‐gel integrates: i) ChSMA scaffold (mechanical support/BMSCs delivery); ii) BC carrier (sustained bFGF release via EGFL/Itga2b and COMP/PI3K/AKT for adhesion/osteogenesis); iii) bFGF/PI3K/AKT/eNOS for angiogenesis. This rational, synergistic design addresses CSD bone regeneration challenges.
Yunze Feng +12 more
wiley +1 more source
Five Things to Know About Obesity in Kidney Transplant Candidates. [PDF]
Zahran S, Lee JY, Singh SKS.
europepmc +1 more source
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård +19 more
wiley +1 more source
After liver transplantation, ischemia‐reperfusion injury is more severe in pericentral regions. Multiomic analyses of human grafts and mouse models identify FOXO1 activation in pericentral hepatocytes as an upstream driver of SAA secretion. SAA recruits and activates FPR2+ macrophages, amplifying local inflammation. Amilo‐5MER inhibits SAA bioactivity,
Feng Zhang +19 more
wiley +1 more source

